Tatton Consulting supported Braintree-based oncology therapeutics company Spirea in its successful application to Biomedical Catalyst 2024 Round 1: Industry-led R&D, which was awarded £474,695 by Innovate UK for the project The development of a new first-in-class cancer therapeutic for difficult-to-treat metastatic Triple Negative Breast.
About the funded R&D project
Development of a new first-in-class cancer therapeutic, building on Spirea’s earlier Innovate UK-supported work on advanced therapies in cancer. First-in-class denotes a mechanism of action not shared by any approved drug, which carries both the highest clinical risk and the strongest commercial position if it succeeds.
Award details
- Grant awarded: £474,695
- Competition: Biomedical Catalyst 2024 Round 1: Industry-led R&D
- Competition year: 2024/25
- Project: The development of a new first-in-class cancer therapeutic for difficult-to-treat metastatic Triple Negative Breast
- Sector: Oncology / therapeutics
- UKRI project record: Gateway to Research, project 10145517
- Dataset: Innovate UK funded projects, published 10 August 2026
Tatton Consulting supported the competitive grant application. The award value, competition and project title above are taken from UKRI’s published record for this project.
See all Innovate UK awards Tatton Consulting has supported on our grant successes page.
